References
- UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet 1998;352:837–53.
- UKPDS Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–13.
- Gwde P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 rando-mised study. Lancet 1999;353: 617–22.
- Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvas-tatin Survival Study (4S). Diabetes Care 1997;20:614–20.
- Tuomilehto J. Controlling glucose and blood pressure in type 2 diabetes. BMJ 2000;321:394–5.
- Stratton IM, Adler Al, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macro-vascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.
- Adler Al, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000;321:412–9.
- Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utiliza-tion. JAMA 1997;278: 1663–9.
- Olivarius NdeF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ 2001;323:970–5.
- Hansen LJ, Olivarius NdeF, Siersma V, Beck-Nielsen H, Pedersen PA. Encouraging structured personalised diabetes care in general practice. A 6-year follow-up study of process and patient outcomes in newly diagnosed patients. Scand J Prim Health Care 2003;21: 89–95.
- Dodsársagerne 1996. Del 1. [Causes of Death in Denmark 1996. Part 1]. Copenhagen: The National Board of Health, 1998.
- Centers for Disease Control and Prevention. National Center for Health Statistics. GMWKI_96. http:// www.cdc.govinchs/data/statab/gmwki_96.pdf
- Van der Does FE, De Neeling JN, Snoek FJ, Kostense PJ, Grootenhuis PA, Bouter LM, et al. Symptoms and well-being in relation to glycemic control in type II diabetes. Diabetes Care 1996;19:204–10.
- Sclar DA, Robison LM, Skaer TL, Dickson WM, Kozma CM, Reeder CE. Sulfonylurea pharmacotherapy regimen adherence in a Medicaid population: influence of age, gender, and race. Diabetes Educ 1999;25:531–8.
- Oster M, Schroll M. Lifestyle and prevention of ischaemic heart disease in Denmark. Changes in knowledge and behaviour 1982-1992. Eur J Publ Health 1995;5: 109–12.
- Olivarius NdeF, Andreasen AH. 5-Year all-cause mortality of 1323 newly diagnosed middle-aged and elderly diabetic patients. Data from the population-based study, "Diabetes Care in General Practice", Denmark. J Diab Comp 1997;11: 83–9.
- Hansen LJ, Olivarius NdeF, Siersma V, Drivsholm T, Andersen JS. Individualised treatment goals in diabetes care. Scand J Prim Health Care 2004;22:71–77.